Key result
Cardiac biomarkers, particularly cardiac troponins I and T, are essential diagnostic tools for the early detection and prognosis of acute myocardial infarction.
This review summarizes the various cardiac biomarkers used for the early serological detection of acute myocardial infarction.
Supports troponin-centric AMI protocols; leaves open prospective validation of emerging biomarker panels.
Acute Myocardial Infarction (AMI) is one of the leading causes of morbidity and mortality worldwide. The greatest risk of fatality occurs within the first hours of initiation of AMI. Thus, the early diagnosis of cardiac ischemia is fundamental for the effective management of AMI patients. Inadequate diagnosis of patients with chest pain often leads to inadequate admission of patients without AMI and vice versa. In addition to the clinical history, physical examination, accurate electrocardiogram findings, and evaluation of cardiac biomarkers play an important role in the early diagnosis of acute ischemia. The present review discusses in detail the various cardiac biomarkers released during the event of an AMI.
No takes yet. Share an insight, caveat, or question.
GH et al. (2016) conducted a review in Acute Myocardial Infarction. Cardiac biomarkers was evaluated. Cardiac biomarkers, particularly cardiac troponins I and T, are essential diagnostic tools for the early detection and prognosis of acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: